GLP1R and type 2 diabetes mellitus: For example, an injectable supramolecular hydrogel depot for a GLP-1 receptor agonist (GLP-1 RA) achieved sustained release for ~42 days in rat models of T2D, corresponding to roughly four months of therapeutic exposure in humans, with glycemic and weight control comparable to daily dosing [123].